[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[S. 3201 Referred in House (RFH)]

<DOC>






116th CONGRESS
  2d Session
                                S. 3201


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 17, 2020

 Referred to the Committee on Energy and Commerce, and in addition to 
the Committees on the Judiciary, and Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 AN ACT


 
     To extend the temporary scheduling order for fentanyl-related 
                  substances, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Temporary Reauthorization and Study 
of the Emergency Scheduling of Fentanyl Analogues Act''.

SEC. 2. EXTENSION OF TEMPORARY ORDER FOR FENTANYL-RELATED SUBSTANCES.

    Notwithstanding any other provision of law, section 1308.11(h)(30) 
of title 21, Code of Federal Regulations, shall remain in effect until 
May 6, 2021.

SEC. 3. STUDY AND REPORT ON IMPACTS OF CLASSWIDE SCHEDULING.

    (a) Definition.--In this section, the term ``fentanyl-related 
substance'' has the meaning given the term in section 1308.11(h)(30)(i) 
of title 21, Code of Federal Regulations.
    (b) GAO Report.--The Comptroller General of the United States 
shall--
            (1) conduct a study of the classification of fentanyl-
        related substances as schedule I controlled substances under 
        the Controlled Substances Act (21 U.S.C. 801 et seq.), research 
        on fentanyl-related substances, and the importation of 
        fentanyl-related substances into the United States; and
            (2) not later than 1 year after the date of enactment of 
        this Act, submit a report on the results of the study conducted 
        under paragraph (1) to--
                    (A) the Committee on the Judiciary of the Senate;
                    (B) the Committee on Health, Education, Labor, and 
                Pensions of the Senate;
                    (C) the Caucus on International Narcotics Control 
                of the Senate;
                    (D) the Committee on the Judiciary of the House of 
                Representatives; and
                    (E) the Committee on Energy and Commerce of the 
                House of Representatives.
    (c) Requirements.--The Comptroller General, in conducting the study 
and developing the report required under subsection (b), shall--
            (1) evaluate class control of fentanyl-related substances, 
        including--
                    (A) the definition of the class of fentanyl-related 
                substances in section 1308.11(h)(30)(i) of title 21, 
                Code of Federal Regulations, including the process by 
                which the definition was formulated;
                    (B) the potential for classifying fentanyl-related 
                substances with no, or low, abuse potential, or 
                potential accepted medical use, as schedule I 
                controlled substances when scheduled as a class; and
                    (C) any known classification of fentanyl-related 
                substances with no, or low, abuse potential, or 
                potential accepted medical use, as schedule I 
                controlled substances that has resulted from the 
                scheduling action of the Drug Enforcement 
                Administration that added paragraph (h)(30) to section 
                1308.11 of title 21, Code of Federal Regulations;
            (2) review the impact or potential impact of controls on 
        fentanyl-related substances on public health and safety, 
        including on--
                    (A) diversion risks, overdose deaths, and law 
                enforcement encounters with fentanyl-related 
                substances; and
                    (B) Federal law enforcement investigations and 
                prosecutions of offenses relating to fentanyl-related 
                substances;
            (3) review the impact of international regulatory controls 
        on fentanyl-related substances on the supply of such substances 
        to the United States, including by the Government of the 
        People's Republic of China;
            (4) review the impact or potential impact of screening and 
        other interdiction efforts at points of entry into the United 
        States on the importation of fentanyl-related substances into 
        the United States;
            (5) recommend best practices for accurate, swift, and 
        permanent control of fentanyl-related substances, including--
                    (A) how to quickly remove from the schedules under 
                the Controlled Substances Act substances that are 
                determined, upon discovery, to have no abuse potential; 
                and
                    (B) how to reschedule substances that are 
                determined, upon discovery, to have a low abuse 
                potential or potential accepted medical use;
            (6) review the impact or potential impact of fentanyl-
        related controls by class on scientific and biomedical 
        research; and
            (7) evaluate the processes used to obtain or modify Federal 
        authorization to conduct research with fentanyl-related 
        substances, including by--
                    (A) identifying opportunities to reduce unnecessary 
                burdens on persons seeking to research fentanyl-related 
                substances;
                    (B) identifying opportunities to reduce any 
                redundancies in the responsibilities of Federal 
                agencies;
                    (C) identifying opportunities to reduce any 
                inefficiencies related to the processes used to obtain 
                or modify Federal authorization to conduct research 
                with fentanyl-related substances;
                    (D) identifying opportunities to improve the 
                protocol review and approval process conducted by 
                Federal agencies; and
                    (E) evaluating the degree, if any, to which 
                establishing processes to obtain or modify a Federal 
                authorization to conduct research with a fentanyl-
                related substance that are separate from the applicable 
                processes for other schedule I controlled substances 
                could exacerbate burdens or lead to confusion among 
                persons seeking to research fentanyl-related substances 
                or other schedule I controlled substances.
    (d) Input From Certain Federal Agencies.--In conducting the study 
and developing the report under subsection (b), the Comptroller General 
shall consider the views of the Department of Health and Human Services 
and the Department of Justice.
    (e) Information From Federal Agencies.--Each Federal department or 
agency shall, in accordance with applicable procedures for the 
appropriate handling of classified information, promptly provide 
reasonable access to documents, statistical data, and any other 
information that the Comptroller General determines is necessary to 
conduct the study and develop the report required under subsection (b).
    (f) Input From Certain Non-Federal Entities.--In conducting the 
study and developing the report under subsection (b), the Comptroller 
General shall consider the views of experts from certain non-Federal 
entities, including experts from--
            (1) the scientific and medical research community;
            (2) the State and local law enforcement community; and
            (3) the civil rights and criminal justice reform 
        communities.

            Passed the Senate January 16, 2020.

            Attest:

                                                JULIE E. ADAMS,

                                                             Secretary.